DZ Bank
NBRV

DZ Bank’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

DZ Bank’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-282
Closed -$355K – 1160
2018
Q1 		$355K Buy
+282
New +$417K ﹤0.01% 848

Other funds holding NBRV

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return

DZ Bank's NBRV Position: Q2 2018 in Review

DZ Bank sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q2 2018, closing a stake of 282 shares — an estimated $355K sold.

DZ Bank first reported a position in NBRV in Q1 2018 and held it in 1 quarter. The position peaked at $355K in Q1 2018. 42 funds tracked by Wall St. Rank hold NBRV as of Q2 2018.

  • DZ Bank reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q2 2018 after selling out during the quarter.
  • DZ Bank sold 282 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q2 2018, an estimated $355K.
  • DZ Bank first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q1 2018 and held it in 1 quarter.
  • DZ Bank's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $355K in Q1 2018.
  • 42 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q2 2018.

Based on DZ Bank's 13F filing for Q2 2018, filed 14 Aug 2018.